TG8-260

Revisión del cliente

Based on 1 Customer Validation

TG8-260 is a second-generation EP2 antagonist developed to alleviate the pathology of central nervous system and peripheral diseases driven by inflammation. TG8-260 can reduce neuroinflammation and gliosis in the hippocampus of rats after pilocarpine-induced persistent epileptic status. Pharmacokinetic data of TG8-260 showed that its plasma half-life was 2.14 hours and its oral bioavailability was 77.3%. TG8-260 is also a potent inhibitor of CYP450 and shows antagonistic activity in inhibiting EP2 receptor-mediated inflammatory gene expression in BV2-hEP2 microglia, which is suitable for studying anti-inflammatory pathways in animal models of peripheral inflammatory diseases.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza : 99.13%
  • No. CAS: 2490544-50-6
  • Fòrmula: C21H20N4O
  • Peso molecular:344.41
  • Almacenamiento:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Actividad biológica
  • Chemical Information
  • Solvente y solubilidad
  • Protocolo
  • Pureza y Documentación
  • Referencias
  • Help & FAQs

Ver todos los productos específicos de isoformas Prostaglandin Receptor

More
MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00